ImmunoCellular Therapeutics, Ltd. Press Releases

IMUC 
$0.4
*  
0.01
2.56%
Get IMUC Alerts
*Delayed - data as of Aug. 27, 2015  -  Find a broker to begin trading IMUC now
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By



ImmunoCellular Therapeutics Reaches Agreement with FDA on Special Protocol Assessment (SPA) for ICT-107 Phase 3 Registrational Trial in Glioblastoma
8/13/2015 6:00:00 AM - PR Newswire
▼-9.09 % Price Change since this news event. The Volume Ratio is 24.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


OUTFRONT Media Reports Second Quarter 2015 Results
8/6/2015 4:01:00 PM - PR Newswire


Cedar Realty Trust Reports Second Quarter 2015 Results
8/6/2015 4:01:00 PM - PR Newswire


ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015
7/23/2015 4:01:00 PM - PR Newswire
▼-23.08 % Price Change since this news event. The Volume Ratio is 1.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma
7/6/2015 6:00:00 AM - PR Newswire
▼-18.37 % Price Change since this news event. The Volume Ratio is 13.12.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




ImmunoCellular Therapeutics to Present at Cantor Fitsgerald Inaugural Healthcare Conference on July 8th
6/29/2015 6:00:00 AM - PR Newswire
▼-16.67 % Price Change since this news event. The Volume Ratio is 1.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial
6/22/2015 6:00:00 AM - PR Newswire
▼-18.37 % Price Change since this news event. The Volume Ratio is 2.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






ImmunoCellular Therapeutics Enters into Manufacturing Agreement with PCT LLC, a Caladrius Company, for US Production of ICT-107 for Phase 3 Registration Trial
6/15/2015 6:00:00 AM - PR Newswire
▼-16.67 % Price Change since this news event. The Volume Ratio is 6.28.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day